A month after announcing the withdrawal from its Phase 3 Alzheimer’s trials, biopharma firm Biogen (NASDAQ: BIIB) on Wednesday reported first-quarter earnings
Biogen Inc.
-(BIIB)
XNAS:BIIB
Biogen ends Alzheimer’s Phase 3 trials, stock plunges above 28%
Shares of the biopharma firms Biogen (NASDAQ: BIIB) and Eisai Co. Ltd (ESALY) plummeted above 28% and 34% respectively at 2 PM
Axsome Therapeutics stock climbs to 34-month high
After the slump on weak quarterly results, investors turned positive on Axsome Therapeutics (AXSM) stock, which climbed to the 34-month high of
ImmunoGen reports Q4 loss; stock gains as results beat estimates
Biotechnology firm ImmunoGen Inc. (IMGN) reported a wider net loss for the fourth quarter, hurt by a sharp fall in revenues. However,
Biogen’s Q4 results beat estimates; revenues up 7%
Biogen Inc. (BIIB) reported revenue and earnings that surpassed market expectations for the fourth quarter of 2018. The stock was up 1.16%
Amgen set to report Q4 earnings on Jan. 29. What’s in store?
Amgen (AMGN) will be reporting its fourth quarter and full-year 2018 earnings results on Tuesday, January 29 after market closes. Analysts expect